Bizarre Patents
An automatic bed maker which uses the expansion of inflatable bladder to straighten, align, and tuck-in bed-cover assembly.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 4689230 | Contraceptive composition for external application Plant extracts are employed to provide a menses inducing composition for topical application. Common commercially available fenugreek seeds and commercially available ginger are mixed in a preferred range of ratios and combined in a dry powder form for to... | 08/25/1987 |
| 4657932 | Method of treating prolactin-related disorders A method of decreasing the concentration of prolactin in an animal, which comprises administering to the animal a prolactin-decreasing amount of cysteamine.... | 04/14/1987 |
| 4585651 | Active/passive immunization of the internal female reproductive organs Antibody or antigen containing microparticles for the active or passive immunization of the internal female reproductive organs, comprising: microparticles of an antigen or antibody incorporated in a matrix material which is biocompatible and biologically... | 04/29/1986 |
| 4542026 | Method of treating vasomotor disorders An agent and method for treating vasomotor disorders, particularly migraine and menstrual pain is provided wherein the method comprises administering to said patient, intravenously or orally, an effective dose of the agent according to the invention, Vita... | 09/17/1985 |
| 4440779 | Tricyclic derivatives of substituted pyrrole acids as analgesic and anti-inflammatory agents Tricyclic derivatives of substituted pyrrole acids, e.g., substituted 4,10-dihydro-10-oxo-1H-[1]benzoxepino[4,3-b]pyrrole-2-acetic acids or the 5-thia analogs thereof have been prepared via hydrolysis of a precursor or decarboxylation of a precursor-diaci... | 04/03/1984 |
| 4439432 | Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols This invention relates to the composition of a biologically compatible high concentration solution of progesterone, which is stable and non-toxic, and which can be used transdermally, orally, and in suppository and pessary form for the correction of proge... | 03/27/1984 |
| 4435420 | Anti-inflammatory agents and antiasthmatic agents N-(1,3-dithiolan-2-ylidene)-4-alkylanilines are useful as anti-inflammatory agents, as analgesic agents and as antiasthmatic agents. The compounds involved can be prepared by the reaction of an appropriate 4-alkylaniline with a methyl(1,3-dithiolan-2-ylid... | 03/06/1984 |
| 4415554 | Treatment for menstrual disorders Use of γ-linolenic acid and related materials alone or with zinc or ଲ-lactam antibiotics to treat menstrual disorders.... | 11/15/1983 |
| 4351846 | 3-Hydroxy and 3-oxo-prostaglandin analogues Prostaglandin analogues of the formula: ##STR1## [wherein R1 represents hydrogen or alkyl of 1 to 12 carbon atoms, R2 represents a single bond or alkylene of from 1 to 5 carbon atoms, R3 represents hydrogen, alkyl or ... | 09/28/1982 |
| 4315033 | Method of treating menopausal symptoms This invention relates to a method of treating vasomotor instability, particularly in relation to the menopausal syndrome, by the administration of methyldopa.... | 02/09/1982 |
| 4291028 | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system A method, formulation, and steroid drug delivery system for the administration of sex steroids for menstrual cycle regulation is disclosed. The invention is useful in clinical applications for pregnancy spacing and treatment of menstrual dysfunction. Prog... | 09/22/1981 |
| 4154730 | Novel 17-spirosultines Novel 17-spirosultines of steroids and the corresponding γ-hydroxy acids of the formula ##STR1## wherein R1 is alkyl of 1 to 4 carbon atoms, A is hydrogen and B is hydrogen or hydroxyl of 댬onfiguration or A and B together form a ... | 05/15/1979 |
| 4152527 | 15-Substituted-ω-pentanorprostaglandins The 15-substituted-ω-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissu... | 05/01/1979 |
| 4145416 | Novel agents and novel methods for treatment of climacteric disturbances Relief from climacteric disturbances is achieved by administration of first a combination of an estrogen of type 1 and an estrogen of type 2, approximately in a ratio of 2:1 to 1:8, daily over 10-12 days; then a combination of an estrogen of type 1 and an... | 03/20/1979 |
| 4117119 | 15-Cyclobutyl-prostaglandins Prostaglandin analogues of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents hydrogen or alkyl of 1 through 12 carbon at... | 09/26/1978 |
| 4076811 | Novel agents and methods for treatment of climacteric disturbances Reliable relief of physical and psychological menopausal disturbances is achieved by administering a combination of estradiol estrogen or derivatives of estradiol (type 1) and estriol or a derivative of estriol (type 2) in a ratio of approximately 1 : 1 t... | 02/28/1978 |
| 4066751 | Prostaglandin analogues Prostaglandin analogues of the formula: ##STR1## wherein X represents oxygen or sulphur, R1 and R2 each represent hydrogen or alkyl of from 1 to 3 carbon atoms, alkenyl of from 2 to 4 carbon atoms or trifluoromethyl, and the dou... | 01/03/1978 |
| 3979440 | Phenacyl-type esters of phenyl-substituted PGE-type compounds Phenacyl-type esters of PGE2, PGE1, and 13,14-dihydro-PGE1 and their 15-methyl, 16,16-dimethyl, and 17-phenyl analogs, including the respective 15(R)epimers, are disclosed, represented by the formula ##EQU1## wherein ... | 09/07/1976 |
| 3965275 | Composition and method A process, and the composition used therein, for estrogenic therapy which comprises administering daily to the patient from about 0.2 to 2000 milligrams of a compound having the formula: ##EQU1## wherein R is selected from the group consisting of hyd... | 06/22/1976 |
| 3932388 | -Azido-4,6-pregnadieno(3,2-c)pyrazoles, processes for their preparation and intermediates useful therein Steroidal 6-azido-4,6-pregnadieno[3,2-c]pyrazoles having glucocorticoid activity are prepared by treating a 6-unsubstituted-4,6-pregnadieno[3,2-c]pyrazole with a halogen azide followed by treatment of the thereby formed 6-azido-7-halogeno-6,7-dihydro... | 01/13/1976 |
